ClinicalTrials.gg
RecruitingNCT02879071MAV-endovascUpdated Jan 22, 2026

Long Term Follow-up After Embolization of Brain Arteriovenous Malformations

An observational study in Arteriovenous Malformations, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

How we know

From the registry’s dates

  • Started Nov 2015; still recruiting 10 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Arteriovenous Malformations with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Malformations · France.

Started
2015
the only one that year
Observational
8 of 15
3 open now
Registered
5th of 15
by date
Lead sponsor
4 of 15
Fondation Ophtalmologique Adolphe de Rothschild

Among the 15 studies in Arteriovenous Malformations with a site in France, this one is the only one that started in 2015, is one of 8 observational ones, and was the 5th registered.

Arteriovenous Malformations

92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.

Browse Arteriovenous Malformations studies →

Open to participants now

6 of the 15 studies in Arteriovenous Malformations with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 19 Arteriovenous Malformations studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arteriovenous Malformations with a site in France, or all of them as a file.
02

Study summary

The time-frame and the follow-up elements after embolization of brain arteriovenous malformations are not standardized. Therefore, few reliable follow-up data are available for these patients. This study aims at collecting standardized long term data for these patients.

03

Conditions studied

  • Arteriovenous Malformations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing embolization for an arteriovenous malformation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • arteriovenous malformation
  • age > 18 years old

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. angiographic evaluation of the arteriovenous malformation occlusion

    Time frame: 5 years after embolization

07

Study locations

1 of 1 sites recruiting
  • Fondation Ophtalmologique Adolphe de Rothschild
    Paris, 75019, France
    Recruiting
    • Raphaël Blanc, MD · Principal investigator
08

References and documents

Publications

  • Baharvahdat H, Blanc R, Fahed R, Pooyan A, Mowla A, Escalard S, Delvoye F, Desilles JP, Redjem H, Ciccio G, Smajda S, Hamdani M, Mazighi M, Piotin M. Endovascular treatment as the main approach for Spetzler-Martin grade III brain arteriovenous malformations. J Neurointerv Surg. 2021 Mar;13(3):241-246. doi: 10.1136/neurintsurg-2020-016450. Epub 2020 Sep 28. PubMed 32989031 ↗
  • Baharvahdat H, Blanc R, Fahed R, Smajda S, Ciccio G, Desilles JP, Redjem H, Escalard S, Mazighi M, Chauvet D, Robert T, Sasannejad P, Piotin M. Endovascular Treatment for Low-Grade (Spetzler-Martin I-II) Brain Arteriovenous Malformations. AJNR Am J Neuroradiol. 2019 Apr;40(4):668-672. doi: 10.3174/ajnr.A5988. Epub 2019 Feb 21. PubMed 30792251 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2015 (actual). Primary completion is estimated for Nov 2037, 263 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2016
First posted
Aug 25, 2016
StartActual
Nov 26, 2015
Primary completionEst.
Nov 25, 2037
CompletionEst.
Nov 25, 2037
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02879071
Responsible party
Sponsor
First posted
Aug 25, 2016
Start date
Nov 26, 2015
Primary completion
Nov 25, 2037 (estimated)
Completion
Nov 25, 2037 (estimated)
Last update
Jan 22, 2026

Study contacts

Amélie Yavchitz, MD
Contact
ayachitz@for.paris
+33 1 48 03 64 54
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion